NCT03719768: Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Radiation Therapy, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older(Adult, Older Adult)
Location of Metastases: Leptomeningeal Disease
Additional Notes: 
Exclusions: Patients with known symptomatic brain metastases requiring steroids; Prior WBRT

Comments are closed.

Up ↑